Enveric Biosciences Highlights Positive Results for EB-003 in PTSD Preclinical Model

Key Terms

neuroplastogenic medical

Neuroplastogenic describes a drug, molecule or treatment that actively promotes neuroplasticity — the brain’s ability to rewire itself by creating or strengthening connections between nerve cells. Think of it as encouraging a tangled garden path to be replanted and smoothed so signals travel more easily; for investors, neuroplastogenic activity can signal potential for lasting benefit in neurological or psychiatric disorders, larger market opportunity, and distinct regulatory and development risks.

5-ht2a medical

5-HT2A is a specific protein on brain cells that acts like a lock for the chemical serotonin, helping control mood, perception, and cognition; when the lock is turned it changes how brain circuits behave. Investors care because many psychiatric and neurological drugs, including certain antidepressants, antipsychotics and experimental psychedelic therapies, target this receptor to produce therapeutic effects or side effects, so drug candidates that affect 5-HT2A can drive clinical value, regulatory risk, and market opportunity.

preclinical model medical

A preclinical model is an experimental system—such as cultured cells, engineered tissues, animals, or computer simulations—used to test a drug or medical product before giving it to people. It’s like a dress rehearsal that checks for basic safety and whether the treatment works at all; investors watch these results because they substantially affect the chance a program will advance, the time and cost to reach human trials, and the likely value of the company’s pipeline.

post-traumatic stress disorder medical

A mental health condition that can develop after a person experiences or witnesses a traumatic event, causing persistent symptoms such as intrusive memories, heightened stress reactions, avoidance of reminders, and trouble sleeping or concentrating. For investors it matters because it can reduce employee productivity, increase healthcare and disability costs, alter consumer behavior, and create demand for treatment and support services—think of a business whose systems keep freezing after a shock, requiring ongoing fixes and higher operating costs.

partial agonism medical

Partial agonism describes a drug’s action at a biological receptor where it activates the receptor but produces a weaker response than a full activator; think of it like a dimmer switch that turns lights on but not to full brightness. For investors, partial agonists can offer a balance between effectiveness and safety—potentially reducing side effects compared with full activators while still providing therapeutic benefit—affecting a drug’s market profile, regulatory pathway, and commercial value.

agonism medical

Agonism is when a drug or molecule binds to a specific cell receptor and activates it, causing the receptor to trigger a biological effect—like a key fitting into a lock and turning it to open a door. For investors, knowing whether a compound works by agonism helps predict how strongly it will affect a disease process, its potential benefits and side effects, and how it might compete with or complement other therapies in the market.

conditioned fear response medical

A conditioned fear response is a learned reaction where a person or animal begins to feel fear when a neutral cue (like a sound or place) is repeatedly paired with something unpleasant, similar to an alarm that goes off after it learns a specific pattern. Investors care because treatments or tests that reduce or measure this learned fear are common drug development and regulatory targets, affecting trial outcomes, approval prospects, and the commercial potential of psychiatric or neurological therapies.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Previously reported results support continued development of EB-003 for PTSD and other neuropsychiatric conditions

Recent U.S. Executive Order supporting psychedelic-inspired therapies highlights growing focus on PTSD and reinforces opportunity for neuroplastogens such as EB-003

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today highlighted preclinical data for its lead candidate, EB-003, a dual 5-HT_2A and 5-HT_1B modulator, in which a single dose of EB-003 significantly reduced context-induced freezing behavior one hour post-dose (p < 0.05). These results indicate a rapid reduction in conditioned fear response in a validated preclinical model of post-traumatic stress disorder (PTSD).

President Donald Trump’s April 18, 2026, Executive Order supporting research into psychedelic therapies for mental health conditions, including PTSD, highlights increasing recognition at the federal level of the urgent need for novel treatment approaches. President Trump stated, “In many cases, these experimental treatments have shown life-changing potential for those suffering from severe mental illness and depression.” Secretary of Health and Human Services Robert F. Kennedy Jr commented, “At the same time, millions of Americans living with depression, PTSD, addiction and other conditions do not respond to existing treatments.”

Joseph Tucker, Ph.D., CEO of Enveric Biosciences, stated: “We believe Enveric’s portfolio of neuroplastogenic compounds, such as EB-003, is well positioned to meet the challenges recognized by regulators and provide therapeutic solutions that fit within existing patient treatment approaches while avoiding real-world limitations of delivering traditional hallucinogenic psychedelic therapies, which may require specialized clinical infrastructure.”

“Enveric’s EB-003 findings in a model of PTSD highlight the potential importance of targeting both neuroplasticity and mood signaling pathways,” Dr. Tucker continued. “We believe EB-003’s combined activity at 5-HT_2A and 5-HT_1B receptors may offer a differentiated approach to promoting neuroplasticity while restoring key signaling pathways involved in emotional regulation and stress response.”

EB-003 is designed as a next-generation neuroplastogen that combines partial agonism at the 5-HT_2A receptor with concomitant agonism of the 5-HT_1B receptor. Prior studies have reported that reduced 5-HT_1B receptor expression and function in key brain regions is associated with increased severity of PTSD symptoms, enhanced comorbidity with major depressive disorder, and greater lifetime trauma burden. Activation of 5-HT_2A receptors has been associated with increased neuroplasticity in brain regions involved in cognition, emotional regulation and decision making. Together, these mechanisms may enable differentiated therapeutic benefit in PTSD and other neuropsychiatric disorders.

About Enveric Biosciences

Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company focused on developing next-generation, small-molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders. By leveraging a differentiated drug discovery platform and a growing library of protected chemical structures, Enveric is advancing a pipeline of novel compounds designed to promote neuroplasticity without hallucinogenic effects. Enveric’s lead candidate, EB-003, is the first known compound designed to selectively engage both 5-HT_2A and 5-HT_1B receptors to deliver fast-acting, durable antidepressant and anxiolytic effects with outpatient convenience.

For more information, please visit www.enveric.com.

Forward-Looking Statements

This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as "plans," "expects" or "does not expect," "proposes," "budgets," "explores," "schedules," "seeks," "estimates," "forecasts," "intends," "anticipates" or "does not anticipate," or "believes," or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, should, would, or might occur or be achieved. Forward-looking statements may include statements regarding beliefs, plans, expectations, or intentions regarding the future and are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the ability of Enveric to: finalize and submit its IND application to the U.S. Food and Drug Administration; carry out successful clinical programs; achieve the value creation contemplated by technical developments; avoid delays in planned clinical trials; establish that potential products are efficacious or safe in preclinical or clinical trials; establish or maintain collaborations for the development of therapeutic candidates; obtain appropriate or necessary governmental approvals to market potential products; obtain future funding for product development and working capital on commercially reasonable terms; scale-up manufacture of product candidates; respond to changes in the size and nature of competitors; hire and retain key executives and scientists; secure and enforce legal rights related to Enveric’s products, including patent protection; identify and pursue alternative routes to capture value from its research and development pipeline assets; continue as a going concern; and manage its future growth effectively.

A discussion of these and other factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric’s filings with the Securities and Exchange Commission, including Enveric’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Enveric disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260505587393/en/

Investor Relations
Tiberend Strategic Advisors, Inc.
David Irish
(231) 632-0002
dirish@tiberend.com

Media Relations
Tiberend Strategic Advisors, Inc.
Casey McDonald
(646) 577-8520
cmcdonald@tiberend.com

Source: Enveric Biosciences